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Vitamin C Intravenous Treatment In the Setting of Atrial
Fibrillation Ablation: Results From the Randomized, Double-Blinded,
Placebo-Controlled CITRIS-AF Pilot Study
Cory R. Trankle, MD; Laura Puckett, RN; Theresa Swift-Scanlan, PhD; Christine DeWilde, PhD; Anna Priday, BS; Robin Sculthorpe, RPh;
Kenneth A. Ellenbogen, MD; Alpha Fowler, MD; Jayanthi N. Koneru, MBBS
Background-—Catheter ablation is an effective treatment for atrial fibrillation (AF), but high levels of post-procedure inflammation
predict adverse clinical events. Ascorbic acid (AA) has shown promise in reducing inflammation but is untested in this population.
We sought to test the feasibility, safety, and preliminary effects on inflammatory biomarkers in the CITRIS-AF (Vitamin C
Intravenous Treatment In the Setting of Atrial Fibrillation Ablation) pilot study.
Methods and Results-—Patients scheduled to undergo AF ablation (N=20) were randomized 1:1 to double-blinded treatment with
AA (200 mg/kg divided over 24 hours) or placebo. C-reactive protein and interleukin-6 levels were obtained before the first
infusion and repeated at 24 hours and 30 days. Pain levels within 24 hours and early recurrence of AF within 90 days were
recorded. Median and interquartile range were aged 63 (56–70) years, 13 (65%) men, and 18 (90%) white. Baseline data were
similar between the 2 groups except ejection fraction. Baseline C-reactive protein levels were 2.56 (1.47–5.87) mg/L and similar
between groups (P=0.48). Change in C-reactive protein from baseline to 24 hours was +10.79 (+6.56–23.19) mg/L in the placebo
group and +3.01 (+0.40–5.43) mg/L in the AA group (P=0.02). Conversely, change in interleukin-6 was numerically higher in the
AA group, though not statistically significant (P=0.32). One patient in each arm developed pericarditis; no adverse events related to
the infusions were seen. There were no significant differences between aggregated post-procedure pain levels within 24 hours or
early recurrence of AF (both P>0.05).
Conclusions-—High-dose AA is safe and well tolerated at the time of AF ablation and may be associated with a blunted rise in
C-reactive protein, although consistent findings were not seen in interleukin-6 levels. Further studies are needed to validate these
findings and explore the potential benefit in improving clinically relevant outcomes.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT03148236. ( J Am Heart Assoc. 2020;9:
e014213. DOI: 10.1161/JAHA.119.014213.)
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A trial fibrillation (AF) is highly prevalent, representing themost common arrhythmia worldwide. Transvenous cathe-
ter-based ablation, using either radiofrequency or cryoballoon
to perform pulmonary vein isolation, is an important option for
treatment of AF.1 However, 35% of patients who undergo AF
ablation have recurrence within 90 days, a phenomenon which
may be caused by the intensity of the inflammatory response
following catheter ablation.2 Early recurrence within 90 days
predicts long-term recurrence of AF.3
Intravenous ascorbic acid (AA) has shown promise as an
adjunct treatment strategy in other disease states with acute
inflammatory spikes, including sepsis,4 percutaneous coro-
nary intervention,5,6 and cardiac surgery.7,8 The effects of AA
during AF ablation are untested. We therefore designed a
phase I pilot study to test the safety and feasibility of AA
treatment at the time of AF ablation, with post-ablation
inflammatory biomarkers as a key end point.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
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From September 2017 to March 2018, consecutive patients
scheduled for a first AF ablation at the Virginia Common-
wealth University Health System were screened for eligibility.
Inclusion criteria included age ≥21 years and willingness to
provide written consent. Exclusion criteria were prior ablation
for AF, active renal calculus, malignancy within 5 years,
autoimmune or autoinflammatory disease, and recent or
active use of immunosuppressive medications. Patients with
diabetes mellitus requiring the use of insulin or with
glycosylated hemoglobin ≥8% were also excluded in this pilot
study because of the potential for high doses of intravenous
AA to interfere with point of care glucose testing.
The study was approved by the Institutional Review Board
at Virginia Commonwealth University and overseen by an
independent Data Safety Monitoring Board. Patients were
approached over the phone in the weeks leading up to their
scheduled ablation procedure and provided written informed
consent on the morning of the ablation. Baseline basic
metabolic profile, C-reactive protein (CRP, measured with a
high-sensitivity assay), interleukin-6 (IL-6), von Willebrand
Factor, and plasma ascorbate levels were obtained the day of
the ablation as the patients were being prepared for the
procedure. Following this, subjects were randomized 1:1 in a
double-blinded fashion to treatment with intravenous AA
(50 mg/kg administered every 6 hours for a total of 4 doses,
with the first dose completed before the ablation procedure)
or matched placebo. Repeat laboratory results were obtained
at 24 hours and 30 days following ablation. Pain levels were
assessed within the first 18 hours following ablation, and
recurrence of AF was recorded for all patients to 90 days
before unblinding. Patients were screened for any adverse
events at all study points (24 hours, 30 days, and 90 days, as
well as 6 and 12 months by phone calls), with particular
attention to any events which could be attributed to AA
infusions such as allergic reactions, renal calculus, or
interference with point-of-care glucose testing. All adverse
events were assessed by the investigators for severity and
potential relationship with the study infusions. The random-
ization order was created by the investigational pharmacy
using a computer-generated sequence in blocks of 10, which
was kept blinded from the study investigators until all
biomarker data were collected and 90-day follow up was
completed. To maintain blindness, the pharmacy staff
prepared all infusions with a shroud to prevent investigators
from discerning any pigmentation of the solution which would
identify the AA infusions. Additionally, the plasma ascorbate
levels were kept blinded from the investigators until the
randomization sequence was unlocked.
Descriptive summaries of continuous measurements are
reported as median and interquartile ranges; descriptive
summaries of categorical measurements are reported as
frequencies and proportions. Continuous and categorical
variables were assessed between allocation groups using
the Mann-Whitney U test and Fisher exact test, respectively.
Wilcoxon Signed Rank test was used to analyze within-group
changes from baseline. Spearman rank order test was used to
evaluate correlations between continuous variables. Unad-
justed P values are reported throughout, with statistical
significance set at the 2-tailed 0.05 level. The Statistical
Package for Social Studies software 25.0 (IBM, Armonk, NY)
was used for all analyses.
Results
Twenty patients provided written informed consent and were
enrolled into the study. Baseline demographics in each group
are shown in Table. Subjects were predominantly in their early
60s and white, with relatively equal split in sex. There was a
slightly higher left ventricular ejection fraction in the ascorbic
acid group and higher use of cryoballoon ablation in the
placebo group, but otherwise baseline data were similar
between the 2 groups, including AA and CRP levels. One
subject in the AA group had insufficient blood volume
obtained to measure 24-hour IL-6 levels and was unable to
return for the 30-day biomarker draw because of logistical
issues; otherwise there was no loss of follow-up, no crossover
between infusion allocations, and no early termination of the
infusions.
Patients treated with AA had a significant rise in AA levels
at 24 hours to 321 (156–629) lmol/L, returning to baseline
levels by 30 days. There was no significant change at any
time point in those receiving placebo.
Subjects allocated to placebo experienced a rise in CRP,
from 3.16 (1.95–8.20) mg/L at baseline to 16.0 (9.40–29.29)
mg/L at 24 hours; those treated with AA were observed to
have a blunted spike in CRP, from 2.59 (1.47–5.19) to 5.31
(4.48–7.92) mg/L, representing changes from baseline of
+10.79 (+6.56 to +23.19) and +3.01 (+0.40 to +5.43) mg/L
in the placebo and AA groups, respectively (P=0.02, Figure).
Both groups experienced increases in interleukin-6 (IL-6)
levels, from 1.51 (1.17–2.48) and 1.65 (0.84–3.10) pg/mL at
baseline to 8.45 (5.10–13.33) and 16.43 (10.06–32.86) at
24 hours for the placebo and AA groups, respectively; though
numerically higher in the AA group, the magnitude of IL-6
change from baseline was not significantly different between
groups (P=0.32). There were no significant within-group or
between-group changes at any time point for von Willebrand
factor levels.
One patient in each group (10%) experienced post-
procedural pericarditis. Sum pain scores within 18 hours of
ablation and early recurrence of AF within 90 days (3 in the
placebo group, 5 in the AA group, P=0.65) were not
significantly different between both groups. There were no
allergic reactions, episodes of renal calculus, issues with
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blood glucose monitoring, or adverse events related to the
study infusions.
Discussion
The data obtained from this pilot study establish safety and
feasibility of high-dose intravenous ascorbic acid at the time of AF
ablation, while suggesting its potential to modulate the inflam-
matory response that occurs after the index procedure. Previous
investigations have demonstrated that AA administration can
reduce markers of oxidative stress, improve microvascular
perfusion in patients undergoing percutaneous coronary
intervention,5,6 as well as reduce postoperative rates of AF
following cardiac surgery.7 To our knowledge, this is the first
evaluation of high-dose AA in patients undergoing AF ablation.
Table. Baseline Characteristics
Placebo (n=10) Ascorbic Acid (n=10) P Value
Epidemiological background
Age, y 65 (54–70) 60.5 (56–69) 0.796
Men 7 (70%) 6 (60%) 0.639
BMI, kg/m2 31 (25–35) 31 (27–34) 0.631
Smoking 2 (20%) 0 (0%) 0.136
Hypertension 4 (40%) 8 (80%) 0.068
Diabetes mellitus 0 (0%) 0 (0%) 1.000
Coronary artery disease 1 (10%) 0 (0%) 0.305
Heart failure 2 (20%) 1 (10%) 0.531
Valvular heart disease 1 (10%) 0 (0%) 0.305
Background medications
Beta blocker 7 (70%) 6 (60%) 0.639
ACE-inhibitor/ARB 1 (10%) 4 (40%) 0.121
Calcium channel blocker 2 (20%) 4 (40%) 0.329
Statin 4 (40%) 4 (40%) 1.000
Oral vitamin C supplement 1 (10%) 1 (10%) 1.000
Echocardiographic and laboratory parameters
LV ejection fraction (%) 55 (45–55) 60 (56–60) 0.035
LA diameter, mm 3.8 (3.5–4.4) 4.0 (4.0–4.9) 0.432
LA area, cm2 26 (17–27) 22 (16–27) 0.556
Ascorbic acid level, lmol/L 48.3 (35.5–70.4) 50.5 (35.2–58.5) 1.000
CRP, mg/L 3.16 (1.95–8.20) 2.59 (1.47–5.19) 0.481
IL-6, pg/mL 1.5 (1.2–2.5) 1.6 (0.8–3.1) 0.905
vWF, lg/mL 16.3 (13.7–20.4) 13.0 (11.3–15.6) 0.278
Procedure-related parameters
Procedure time, min 152 (124–164) 151 (114–190) 1.000
Ablation time, s 1756 (1387–2658) 2464 (1620–2778) 0.481
Mode of ablation 0.028
RFA 5 (50%) 9 (90%)
Cryoballoon 5 (50%) 0 (0%)
Both 0 (0%) 1 (10%)
Acute PV isolation success 10 (100%) 9 (90%) 0.305
Non-inducibility of AF after ablation 10 (100%) 10 (100%) 1.000
ACEi indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; CRP, high sensitivity
C-reactive protein; IL-6, interleukin-6; LA, left atrium; LV, left ventricle; PV, pulmonary vein; RFA, radiofrequency ablation; vWF, von Willebrand factor.
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Blunting the sterile inflammatory response that follows AF
ablation could have beneficial effects, including potentially
reducing the chances of early or late recurrence of AF. Indeed,
the degree of inflammatory biomarker elevation following AF
ablation predicts early recurrence of AF,2 which itself predicts
long-term recurrence of AF.3 Prior studies using colchicine
have shown promise in reducing inflammatory biomarkers
after AF ablation, which has been associated with improved
rates of early recurrence in the first study with 161 patients9
and mid-term recurrence in the follow-up study with 223
patients.10 While this is an encouraging strategy to use as an
adjunct to ablation, the side effect profile, drug-drug interac-
tion potentials, and real-world pricing issues involved with
colchicine should prompt investigations into alternative anti-
inflammatory agents to improve on these factors.
It is notable that not all prior studies with anti-inflammatory
treatment strategies have shown reductions in recurrent AF.
For example, in a randomized clinical trial of 125 patients
undergoing AF ablation, Suleiman et al demonstrated that
patients who received atorvastatin 80 mg daily starting on
postoperative day 1 experienced a decrease in CRP levels at
30 days compared with those randomized to placebo, without
significant differences in recurrences in AF.11 Additionally,
intravenous AA has previously been studied alone or in
combination with other antioxidant supplements; whether the
present agent and dosing strategy is most efficacious in
achieving the safe anti-inflammatory effect remains to be
determined. Nonetheless, in the present study the AA
infusions were initiated before ablation (and the blunted
CRP rise noted by postoperative day 1), which may optimally
position the treatment strategy to more rapidly resolve early
sterile inflammation related to the procedure. Whether this
results in clinically relevant improvements (ie, reduced rates
of AF recurrence) is unknown.
Limitations to this study include small sample size (limiting
power to detect clinically relevant outcomes) and conduct at a
single center. Biomarkers were only collected at 24 hours and
30 days following the ablation; it is thus uncertain whether
Figure. Effects on biomarkers. Trends in ascorbate levels (A), C-reactive protein (B), and interleukin-6 (C) based on allocation group at baseline
as well as 24 hours and 30 days following ablation. Relationship between changes in ascorbate levels and C-reactive protein from baseline to
24 hours (D). Changes in C-reactive protein (E) and interleukin-6 (F) from baseline to 24 hours based on allocation group. AA indicates ascorbic
acid; CRP, C-reactive protein; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin-6. Data are represented as medians and interquartile
ranges.
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high-dose AA may have had an effect on IL-6 levels at day 4,
which Deftereos et al found predictive of future recurrence.9
In addition, while there was a significant difference in change in
CRP between groups in favor of AA, there was a somewhat
discordant finding (albeit not statistically significant) in the IL-6
values; the significance of this is unclear, and could be
elucidated with larger sample sizes as well as additional blood
sample time points to more comprehensively describe the rise
and fall of the inflammatory biomarkers—and whether those
responses may be modified by high-dose AA. Finally, there was
a significantly higher proportion of patients in the placebo
group who underwent cryoablation as opposed to radiofre-
quency ablation, although this might have actually resulted in
lower inflammatory biomarker levels in the placebo group
because of the expected lower degree of inflammatory
response and thus diluted the potential anti-inflammatory
effect of AA. Nonetheless, cryoablation remains an important
modality of pulmonary vein isolation for clinical use, and larger
sample sizes in future studies that are similarly randomized
(perhaps additionally stratified based on anticipated ablation
modality) would be better positioned to avoid such differences
between treatment groups and remove this confounder. Larger
studies, possibly comparing high-dose intravenous AA with
other anti-inflammatory strategies such as colchicine, are
warranted to expand on these findings and explore effects on
both short- and long-term clinical outcomes.
Conclusions
High dose ascorbic acid is safe and feasible at the time of
catheter ablation for atrial fibrillation and may blunt the rise in
CRP 24 hours following the procedure. Future studies are
warranted to better characterize the effects of this treatment
strategy on the inflammatory response and to explore its
effects on clinical outcomes.
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